Buy Bronchogen Research Peptide

What is Bronchogen?

Bronchogen is a synthetic four-amino-acid peptide (Ala-Glu-Asp-Leu) from the Russian peptide bioregulator research program, designed to target lung and airway tissue. It is studied in laboratory research for its effects on airway-lining cell signaling.

• A short synthetic peptide (Ala-Glu-Asp-Leu) from the Russian bioregulator research program
• Studied in laboratory research for its effects on airway-lining cell signaling and gene activity
• One of a family of short peptides each studied in a specific tissue type
• Investigated alongside other organ-specific bioregulators from the same program

For research use only. Not approved for human therapeutic use.

Bronchogen, also known by its tetrapeptide designation AEDL (Ala-Glu-Asp-Leu), is a synthetic tetrapeptide bioregulator with the molecular formula C18H30N4O9 and a molecular weight of 446.45 g/mol. Developed at the Saint Petersburg Institute of Bioregulation and Gerontology as part of the Khavinson peptide bioregulator series, Bronchogen was designed based on peptide fractions isolated from murine bronchial mucosa. Its sequence, Ala-Glu-Asp-Leu, extends the AED core motif with a C-terminal leucine residue. The AEDL sequence has been the subject of biophysical studies examining its interaction with DNA, with published research reporting binding at guanine N7 sites within the major groove without visible distortion of the double helix structure. Produced via solid-phase peptide synthesis, Bronchogen is associated with bronchial epithelial gene expression and pulmonary tissue signalling pathways.

Bronchogen is an organ-specific tetrapeptide bioregulator within the Khavinson framework. A dedicated in vitro study has documented Bronchogen-specific effects on bronchial epithelial gene expression: in cultured human bronchial epithelial cells, the tetrapeptide upregulated a panel of genes governing bronchial epithelial differentiation and alongside markers of epithelial functional activity [1]. At the molecular level, consistent with the proposed direct-to-DNA mode of action, biophysical work on the isolated peptide has documented that Bronchogen binds double-stranded DNA in the major groove at the guanine N7 position, forming a complex without visible distortion of the double-helix structure [2], making Bronchogen a reference compound in preclinical respiratory research examining bronchial epithelial differentiation and gene expression, peptide–DNA interaction at defined nucleotide sites, and organ-specific short-peptide regulation of pulmonary gene expression.

Bronchogen is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Khavinson VK, Tendler SM, Vanyushin BF, Kasyanenko NA, Kvetnoy IM, Linkova NS, et al. Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. 2014 Oct;192(5):781–91. .PubMed PMID: 250151712Khavinson VK, Soloviev AY, Morozova EA, Lin’kova NS, Kasyanenko NA. In vitro interaction of the AEDL peptide with DNA. Journal of Structural Chemistry. 2017 Mar 1;58(2):420–4.doi:10.1134/S0022476617020299

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →

Bronchogen, also known by its tetrapeptide designation AEDL (Ala-Glu-Asp-Leu), is a synthetic tetrapeptide bioregulator with the molecular formula C18H30N4O9 and a molecular weight of 446.45 g/mol. Developed at the Saint Petersburg Institute of Bioregulation and Gerontology as part of the Khavinson peptide bioregulator series, Bronchogen was designed based on peptide fractions isolated from murine bronchial mucosa. Its sequence, Ala-Glu-Asp-Leu, extends the AED core motif with a C-terminal leucine residue. The AEDL sequence has been the subject of biophysical studies examining its interaction with DNA, with published research reporting binding at guanine N7 sites within the major groove without visible distortion of the double helix structure. Produced via solid-phase peptide synthesis, Bronchogen is associated with bronchial epithelial gene expression and pulmonary tissue signalling pathways.

Bronchogen is an organ-specific tetrapeptide bioregulator within the Khavinson framework. A dedicated in vitro study has documented Bronchogen-specific effects on bronchial epithelial gene expression: in cultured human bronchial epithelial cells, the tetrapeptide upregulated a panel of genes governing bronchial epithelial differentiation and alongside markers of epithelial functional activity [1]. At the molecular level, consistent with the proposed direct-to-DNA mode of action, biophysical work on the isolated peptide has documented that Bronchogen binds double-stranded DNA in the major groove at the guanine N7 position, forming a complex without visible distortion of the double-helix structure [2], making Bronchogen a reference compound in preclinical respiratory research examining bronchial epithelial differentiation and gene expression, peptide–DNA interaction at defined nucleotide sites, and organ-specific short-peptide regulation of pulmonary gene expression.

Bronchogen is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Khavinson VK, Tendler SM, Vanyushin BF, Kasyanenko NA, Kvetnoy IM, Linkova NS, et al. Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. 2014 Oct;192(5):781–91. .PubMed PMID: 250151712Khavinson VK, Soloviev AY, Morozova EA, Lin’kova NS, Kasyanenko NA. In vitro interaction of the AEDL peptide with DNA. Journal of Structural Chemistry. 2017 Mar 1;58(2):420–4.doi:10.1134/S0022476617020299

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS NumberN/A (Khavinson bioregulator)Molecular Weight446.47 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKURSC-BRONCHOGEN-2296

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.

Bronchogen, also known by its tetrapeptide designation AEDL (Ala-Glu-Asp-Leu), is a synthetic tetrapeptide bioregulator with the molecular formula C18H30N4O9 and a molecular weight of 446.45 g/mol. Developed at the Saint Petersburg Institute of Bioregulation and Gerontology as part of the Khavinson peptide bioregulator series, Bronchogen was designed based on peptide fractions isolated from murine bronchial mucosa. Its sequence, Ala-Glu-Asp-Leu, extends the AED core motif with a C-terminal leucine residue. The AEDL sequence has been the subject of biophysical studies examining its interaction with DNA, with published research reporting binding at guanine N7 sites within the major groove without visible distortion of the double helix structure. Produced via solid-phase peptide synthesis, Bronchogen is associated with bronchial epithelial gene expression and pulmonary tissue signalling pathways.

Bronchogen is an organ-specific tetrapeptide bioregulator within the Khavinson framework. A dedicated in vitro study has documented Bronchogen-specific effects on bronchial epithelial gene expression: in cultured human bronchial epithelial cells, the tetrapeptide upregulated a panel of genes governing bronchial epithelial differentiation and alongside markers of epithelial functional activity [1]. At the molecular level, consistent with the proposed direct-to-DNA mode of action, biophysical work on the isolated peptide has documented that Bronchogen binds double-stranded DNA in the major groove at the guanine N7 position, forming a complex without visible distortion of the double-helix structure [2], making Bronchogen a reference compound in preclinical respiratory research examining bronchial epithelial differentiation and gene expression, peptide–DNA interaction at defined nucleotide sites, and organ-specific short-peptide regulation of pulmonary gene expression.

Bronchogen is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Khavinson VK, Tendler SM, Vanyushin BF, Kasyanenko NA, Kvetnoy IM, Linkova NS, et al. Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. 2014 Oct;192(5):781–91. .PubMed PMID: 250151712Khavinson VK, Soloviev AY, Morozova EA, Lin’kova NS, Kasyanenko NA. In vitro interaction of the AEDL peptide with DNA. Journal of Structural Chemistry. 2017 Mar 1;58(2):420–4.doi:10.1134/S0022476617020299

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS NumberN/A (Khavinson bioregulator)Molecular Weight446.47 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKURSC-BRONCHOGEN-2296

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.